Business
ENDRA Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update
Conference call begins at 4:30 p.m. Eastern time todayANN ARBOR, MI / ACCESSWIRE / August 12, 2021 / ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a
About this update from Endra Life Sciences Inc.
[{"type":"text","content":"Conference call begins at 4:30 p.m. Eastern time todayANN ARBOR, MI / ACCESSWIRE / August 12, 2021 / ENDRA Life Sciences Inc. (\"ENDRA\") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended June 30, 2021 and provided a business update. Highlights of the second quarter of 2021 and recent weeks include the following:Continued to screen patients at Rocky Vista University College of Osteopathic Medicine (\"RVUCOM\").In addition, the University of Pittsburgh Medical Center (\"UPMC\") is scheduled to commence scanning patients in the near term as it completes its pandemic-related backlog of MRI procedures. All clinical evaluation sites will compare liver fat measurements from the TAEUS system with the gold standard, MRI-PDFF. RVUCOM's study is targeting a total of 200 patients and UPMC is targeting 75 patients.Initiated in-person sales activities for the TAEUS system in Europe. Four salespeople are driving TAEUS' marketing and sales efforts in Europe targeting ENDRA's database of prospective customers.Strengthened TAEUS intellectual property protection with issuance of additional U.S. patents. In July, ENDRA announced the issuance of three additional U.S. patents. Another U.S. patent was recently issued that further protects the company's TAEUS technology and increases the year-to-date total to eight issued patents. ENDRA's intellectual property portfolio continues to grow and currently stands at 87 global assets, defined as patents in preparation, filed or issued.Appointed Irina Pestrikova as Senior Director of Finance. Ms. Pestrikova has supported ENDRA since 2014 and has been actively involved in ENDRA's financial planning and analysis, accounting and SEC reporting. Ms. Pestrikova is assuming all day-to-day responsibilities previously performed by ENDRA's former Chief Financial Officer, David Wells.\"ENDRA is well-capitalized and we are putting in place the building blocks for the global success of our Thermo Acoustic Enhanced UltraSound technology. Although certain elements are out of our control, including regulatory processes and the COVID-19 pandemic, we are focused on advancing our commercial plans for TAEUS in Europe and supporting our clinical evaluation sites worldwide, as well as remaining highly responsive to the FDA regarding our 510(k) sub...